Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the develop... Read more
Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development... Read more
Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development... Read more
Y-mAbs Therapeutics, Inc. today announced that it will report its financial results for the first quarter... Read more
Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development... Read more
This article written by Jan Bjerrum Bach, Attorney-at-law, Jusmedico Law Firm / BioLawEurope will give... Read more
Y-mAbs Therapeutics, Inc. a late-stage clinical biopharmaceutical company focused on the development... Read more
Servier, an independent international pharmaceutical company, announced today that it has entered into... Read more
On April 01, 2020, Y-mAbs announced that the Company has completed the submission of its Biologics License... Read more